These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39321707)

  • 1. Earlier intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome.
    Ji Q; Dong Y; Zhang Y; Wu X; Bai Z; Huang S; Dong X; Wang Y; Pan J; Lu J; Hu S; Wu S
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113214. PubMed ID: 39321707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome.
    Asawa P; Vusqa U; Khan C; Samhouri Y; Fazal S
    Anticancer Res; 2022 Aug; 42(8):3853-3856. PubMed ID: 35896259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
    Katsin M; Shman T; Migas A; Lutskovich D; Serada Y; Khalankova Y; Kostina Y; Dubovik S
    Front Immunol; 2024; 15():1380451. PubMed ID: 38765003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
    Shalabi H; Harrison C; Yates B; Calvo KR; Lee DW; Shah NN
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30741. PubMed ID: 37897136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy.
    Larue M; Bouvier A; Maillard A; Cuffel A; Allain V; Ursu R; Carpentier AF; Azoulay E; Thieblemont C; Di Blasi R; Caillat-Zucman S
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39317455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
    Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
    Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
    Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
    Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
    Gu T; Hu K; Si X; Hu Y; Huang H
    WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W
    Cancer; 2024 Aug; 130(15):2660-2669. PubMed ID: 38578977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.
    Tang JP; Lafeuille P; Socolov A; Diamond SS; Aptekar J; Moore TB; Nie EH; Hanudel MR; Nowicki TS
    Cancer Res Commun; 2024 Oct; 4(10):2589-2597. PubMed ID: 39269033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
    Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
    Cytotherapy; 2024 Sep; 26(9):1026-1032. PubMed ID: 38819365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
    Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
    Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in CAR T Cell-Associated Neurotoxicity.
    Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ
    Front Immunol; 2020; 11():577027. PubMed ID: 33391257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
    Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
    Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
    Sesques P; Kirkwood AA; Kwon M; Rejeski K; Jain MD; Di Blasi R; Brisou G; Gros FX; le Bras F; Bories P; Choquet S; Rubio MT; Iacoboni G; O'Reilly M; Casasnovas RO; Bay JO; Mohty M; Joris M; Abraham J; Castilla Llorente C; Loschi M; Carras S; Chauchet A; La Rochelle LD; Hermine O; Guidez S; Cony-Makhoul P; Fogarty P; Le Gouill S; Morschhauser F; Gastinne T; Cartron G; Subklewe M; Locke FL; Sanderson R; Barba P; Houot R; Bachy E
    J Hematol Oncol; 2024 Aug; 17(1):61. PubMed ID: 39107847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.